Key Highlights

  • Surgery Partners (NASDAQ:SGRY) closed at USD 23.16, down 0.02% on the latest session, and sits up 72.41% over one month, ranking No. 1 among mid caps in a published screener snapshot.
  • HealthSpan Partners, an affiliate of Bon Secours Mercy Health, agreed on October 26, 2026 to buy the company for USD 23.50 per share in cash, a deal valued at USD 5.7 billion.
  • The shares closed at USD 23.25 on October 26, 2026, up 47.62%, against a prior close of about USD 15.75 (calculated), and the 52-week range is USD 11.41 to USD 23.37.
  • Bain Capital holds roughly 39% of the shares, and closing is expected in the first quarter of 2027, so the stock now trades like a deal spread, not a growth story.

What Moved Surgery Partners (Up 72.41% in a Month)

The move is a takeover. On October 26, 2026, HealthSpan Partners agreed to acquire Surgery Partners for USD 23.50 per share in cash, a deal valued at USD 5.7 billion. The stock closed that Monday at USD 23.25, up 47.62%, within a session range of USD 23.19 to USD 23.25. Published coverage cited Volume of 58.3 million shares against an average of about 3.3 million. At USD 23.16 on the snapshot, the gap to the offer is USD 0.34, or about 1.5% (simple arithmetic on two published numbers). The 3M gain is 53.96% and the 6M gain is 61.81%.

Why Surgery Partners Re-Rated: Cash Takeover Mechanics

The rationale is a cash buyout. When an acquirer offers a fixed price, the target shares reprice toward that offer less a discount for time and risk, so the move arrives in one session. The remaining spread of USD 0.34 reflects the wait until the first quarter of 2027, the need for Shareholder and regulatory approvals, and a small chance the deal fails. Bain Capital, with roughly 39% of the stock, is reported to support the transaction, which lowers voting risk. The offer implies a premium near 49% to the prior close (calculated). The earlier path from USD 11.41 to USD 23.37 over 52 weeks shows how much of the gain came from the bid, with the 1W change only down 0.41% since the price is anchored.

Valuation, Liquidity and Risks After a 72% Run

Published coverage put the Market Value of the publicly traded shares near USD 2.99 billion, inside the USD 2 billion to USD 10 billion Mid cap band, with a three month average volume of about 3.1 million shares. Because the price is capped by the cash offer, upside above USD 23.50 looks limited and the main risk is the downside if the deal slips or breaks, where the shares could move back toward pre-bid levels near USD 15.75. The 52-week high of USD 23.37 sits just USD 0.21 above the snapshot price (calculated). Regulators could ask for changes, financing is all cash, and any delay stretches the time value. After a gain like this, trading can be thin once the arbitrage buyers hold the float, and a small number of trades can move the price when spreads widen.

Where Things Stand

The surge reflects a cash takeover, not an operating re-rating. Surgery Partners (NASDAQ:SGRY) is the number one mid cap gainer over one month in the snapshot, up 72.41%, and trades at USD 23.16, about 1.5% under the USD 23.50 offer. With the 1W move at down 0.41%, the stock is now tied to deal timing, expected in the first quarter of 2027, not to earnings. The move should not be read as a sign that it will continue, and a failed deal is the main risk.